Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
MWN-AI** Summary
Nyxoah SA, a Belgium-based medical technology company specializing in innovative treatments for Obstructive Sleep Apnea (OSA), has made a significant advancement in its Middle Eastern operations. On February 18, 2026, Nyxoah announced a Memorandum of Understanding (MoU) with Sheikh Shakhbout Medical City Hospital (SSMC), a top healthcare facility in the United Arab Emirates, focused on enhancing therapy management for OSA and expediting access to Nyxoah's Genio® system.
This collaboration is part of Nyxoah's strategy to work with premier medical centers to broaden the reach of its hypoglossal nerve stimulation therapy, known for its effectiveness in treating OSA. Specifically, the agreement aims to position SSMC as a key regional hub for Genio therapy, developing a robust implant program centered on patient care. Moreover, plans are in motion to transform SSMC into a regional training center for healthcare professionals, including surgeons and sleep specialists, to advance knowledge and application of this innovative therapy.
Olivier Taelman, the CEO of Nyxoah, highlighted the importance of this initiative given the high rates of OSA in the Middle East and emphasized the need for new treatment options that also consider the potential connections to chronic diseases like type 2 diabetes. Dr. Marwan Al Kaabi, CEO of SSMC, echoed this sentiment, underscoring their commitment to enhancing specialized care and fostering research in innovative sleep apnea treatments.
With Nyxoah’s Genio system already CE marked and recently FDA approved for certain patient populations, the partnership is poised to elevate OSA management standards while offering state-of-the-art education to healthcare providers in the region. This MoU reflects Nyxoah’s vision to improve patient outcomes and contribute to the evolving landscape of sleep disorder treatment.
MWN-AI** Analysis
Nyxoah’s recent Memorandum of Understanding (MoU) with Sheikh Shakhbout Medical City Hospital marks a strategic advancement in the company’s efforts to penetrate the Middle East market for Obstructive Sleep Apnea (OSA) treatments. This collaboration is not only pivotal for increasing patient access to Nyxoah's Genio® hypoglossal nerve stimulation therapy but also positions SSMC as a regional center of excellence for OSA management.
Investors should view this partnership positively as it underscores Nyxoah's commitment to expanding its footprint in a region where OSA prevalence is high. The establishment of a high-volume implant program and a training hub for healthcare providers will enhance the credibility of the Genio system and potentially increase its adoption rates. Additionally, the focus on clinical research and collaboration may open doors for further innovations and product enhancements, aligning with Nyxoah’s focus on patient-centered care.
This action aligns with the company's goals established following its successful completion of key studies that led to regulatory approvals in Europe and the United States. The FDA’s approval for a subset of adult patients with moderate to severe OSA is particularly noteworthy as it enhances the target market for Nyxoah’s products.
Despite the promising developments, investors should remain cautious. Market dynamics, regulatory challenges, and competitive pressures from established players in the neuromodulation space might impact Nyxoah's performance. Investors should keep an eye on the company's ability to execute its strategy effectively and maintain its momentum in both R&D and market penetration efforts.
In conclusion, while Nyxoah presents a potentially lucrative opportunity in a growing market, a careful consideration of external market factors, competitive landscape, and execution risks will be crucial for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
Mont-Saint-Guibert, Belgium – February 18, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced continued progress in strengthening its presence in the Middle East through the signature of a Memorandum of Understanding (MoU) with Sheikh Shakhbout Medical City (SSMC), a flagship hospital in the United Arab Emirates for serious and complex care and a subsidiary of PureHealth, the largest healthcare group in the Middle East. This MoU reflects Nyxoah’s strategic focus on working with leading regional medical centers to expand access to its Genio® hypoglossal nerve stimulation (HGNS) therapy, while supporting the highest standards of clinical care, education, and scientific collaboration.
As part of this MoU, Nyxoah and SSMC are engaged in initiatives aimed at positioning SSMC as a leading regional center for Genio therapy. These efforts are intended to support the development of a high-volume implant program with a strong focus on patient-centered care.
In parallel, the collaboration includes plans to establish SSMC as a regional training hub for Genio therapy in the Middle East to support the education of surgeons, sleep physicians, and referring healthcare professionals from across the region.
Nyxoah and SSMC are also engaged in discussions to explore clinical research and collaboration in the field of sleep apnea, chronic and metabolic disease management.
Olivier Taelman, Chief Executive Officer of Nyxoah, commented: “Given the high prevalence of Obstructive Sleep Apnea in the Middle East, this initiative supports our vision to offer new treatment options to patients in the region and further explore the impact of advanced OSA management on chronic and metabolic diseases such as type 2 diabetes. Our active engagement with Sheikh Shakhbout Medical City reflects our strategy of partnering with leading institutions to build sustainable clinical programs, support physician education, and contribute to the advancement of care for patients living with obstructive sleep apnea.”
Dr. Marwan Al Kaabi, Chief Executive Officer of Sheikh Shakhbout Medical City, added: “At Sheikh Shakhbout Medical City, we are committed to advancing specialized, high-quality care through clinical excellence, education, and research. Our collaboration with Nyxoah supports our efforts to further develop expertise in innovative sleep apnea therapies and to serve as a regional reference center for training and scientific exchange.”
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Contacts:
Nyxoah
John Landry, CFO
IR@nyxoah.com
Rémi Renard
Head of Investor Relations & Corporate Communication
IR@nyxoah.com
Attachment
FAQ**
How does the Memorandum of Understanding between Nyxoah SA NYXH and Sheikh Shakhbout Medical City Hospital aim to enhance patient-centered care for Obstructive Sleep Apnea therapy in the Middle East?
What specific initiatives will Nyxoah SA NYXH and SSMC implement to establish SSMC as a leading training hub for Genio therapy in the region?
In the context of the partnership, how does Nyxoah SA NYXH plan to collaborate on clinical research related to OSA and its association with chronic and metabolic diseases?
What are the expected outcomes for Nyxoah SA NYXH and its Genio therapy following the signature of this MoU, considering the high prevalence of OSA in the Middle East?
**MWN-AI FAQ is based on asking OpenAI questions about Nyxoah SA (NASDAQ: NYXH).
NASDAQ: NYXH
NYXH Trading
-5.81% G/L:
$3.24 Last:
22,444 Volume:
$3.49 Open:
